PART 1 IMMUNOLOGY 1.1 Pathophysiology of atopic excema in humans 1.2 Mechanism of lesion formation in canine atopic dermatitis: 2004 hypothesis 1.3 Expression of Th1-cytokine mRNA in canine atopic dermatitis correlates with severity of clinical lesions 1.4 IgE and IgG antibodies to food antigens in sera from normal dogs, dogs with atopic dermatitis and dogs with adverse food reactions 1.5 Evaluation of a rapid, quantitative, allergen-specific IgE screening immunoassay in dogs with atopic dermatitis 1.6 Comparison of intradermal testing and allergen-specific IgE serum testing in dogs with warm-weather, seasonal atopic dermatitis 1.7 Patch test reactions to house dust mites in dogs with atopic dermatitis 1.8 ? 1.9 Dermatophagoides farinae-specific IgG subclass responses in atopic dogs undergoing allergen-specific immunotherapy 1.10 Effect of treatment with recombinant canine IFn on the clinical signs, histopathology, and Th1 / Th2-cytokine mRNA profiles in Shih tzu dogs and a basset hound with atopic dermatitis 1.11 Effects of the immunomodulatory drugs tacrolimus, rapamycin, and cilomilast on dendritic cell function in a rodent model of allergic contact dermatitis 1.12 Temporal development on ovine cutaneous hypersensitivity responses to Psoroptes ovis (sheep scab mite) PART 2 THERAPY 2.1 Immunomodulatory Therapy 2.2 Lufenuron does not augment effectiveness of terbinafine for treatment of Microsporum canis infections in a feline model 2.3 An overview of pharmacokinetic and pharmacodynamic studies in the development of itraconazole for feline Microsporum canis dermatophytosis 2.4 Evaluation of cephalexin intermittent therapy (weekend therapy) in the control of recurrent idiopathic pyoderma in dogs: a randomised, double-blinded, placebo-controlled study 2.5 Comparison of bacterial organisms from otic exudates and ear tissue from the middle ear of untreated and enrofloxacin-treated dogs with end-stage otitis 2.6 ? 2.7 Diagnosis and treatment of pituitary pars intermedia dysfunction (classical Cushing's disease) and metabolic syndrome (peripheral Cushing's syndrome) in horses PART 3 NUTRITION 3.1 A randomised, controlled, double-blinded, multicentre study on the efficacy of a diet rich in fish oil and borage oil in the control of canine atopic dermatitis PART 4 SKIN BIOLOGY 4.1 ? 4.2 Optical biopsy: non-invasive tissue evaluation utilising optical coherence tomography 4.3 Influence of purinergic substances on proliferation of murine keratinocytes and full-thickness skin healing 4.4 Factors associated with Malassezia colonisation in the ear canals of dogs without clinical signs of otitis externa PART 5 INFECTIOUS AND PARASITIC DISEASES 5.1 Mycobacterial diseases of cats and dogs 5.2 ? 5.3 Rhodococcus spp. as ubiquitous contaminants of paraffin-embedded tissues in PCR analysis for Mycobacterium spp. skin infections 5.4 In Vivo mRNA expression analysis of Microsporum canis secreted subtilisin-like serine proteases in feline dermatophytosis 5.5 Real-time PCR for monitoring cutaneous asymptomatic carriage of Leishmania spp. in laboratory mice 5.6 Adherence of Staphylococcus intermedius to canine corneocytes involves a protein-protein interaction that is sensitive to trypsin, but resistant to cold 5.7 Retrospective histopathological and clinical characterisation of a dermatopathy associated with toxic shock-like syndrome in dogs PART 6 WORKSHOPS 6.1 Canine Hypothyroidism 6.2 Leishmaniasis and other arthropod-vectored diseases 6.3 Parasites and antiparasitic drugs 6.4 Anti-fungal therapy 6.5 New developments in dermatopathological diagnosis 6.6 Pseodomonas otitis 6.7 Neoplastic and paraneoplastic skin diseases 6.8 Food allergy: hydrolysed vs. limited-antigen diets 6.9 New forms of therapy for atopic dermatitis 6.10 Equine allergic disease 6.11 Genodermatosis: alopecia and hypothricoses 6.12 Therapy of recurrent pyoderma and immunostimulants 6.13 Rodent and rabbit dermatology 6.14 Shampoos and topical therapy
